Preclinical and clinical development pipeline

Target: PDE10

Phase I Topline data readout: Q1 2024

Target Market: Moderate-to-severe Ulcerative Colitis

Potential Key Differentiators: 

• Novel therapeutic approach: potential first-in-class peripherally restricted small molecule for the treatment of UC
• Potential for meaningful differentiation from existing immunosuppressive standard-of care treatments, through disease modifying efficacy

Target: CHK1

IND-ready: Q4 2023

Target Market: Naive and recurrent GBM regardless of MGMT methylation status

Potential Key Differentiators:

• Potential first-in-class CNS penetrant drug for GBM and metastatic brain tumours
• Potential efficacy in patients resistant to chemotherapeutic SoC agents
• Strong rationale for combination therapy approaches in non-CNS cancers

Amyotrophic Lateral Sclerosis

Target: RAR⍺β

IND-ready: Q2 2024

Target Market: Sporadic and familial forms of ALS 

Potential Key Differentiators:

• Potential best-in-class CNS penetrant subtype-selective approach to drive efficacy and minimise side effect profile
• Neuroprotective mechanism of action, with positive effects in SOD1 mouse model 

Novel target

Target Market: Parkinson's and related synucleinopathies

Potential Key Differentiators: 

• Potential first-in-class CNS penetrant drug with neuroprotective activity

Novel Target

Target Market: Fibrotic indications including NASH

Potential Key Differentiators: 

• Novel target focused on the underlying mechanisms of fibrotic diseases - broad spectrum therapeutic potential

Mutliple Targets

• Financial upside through potential future development milestone payments and royalties post commercialisation
• Further AZ target selection potential across Heart Failure and Systemic Lupus Erythematosus

Multiple targets

• Financial upside through potential future development milestone payments and royalties post commercialisation
• Further AZ target selection potential across Heart Failure and Systemic Lupus Erythematosus

Multiple Targets.

Initial delivery of 3 novel small molecule drug candidates.